A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis

mBio

Volumn 8, Issue 1, 2017, Pages

  Bielecka, Magdalena K ^a   Tezera, Liku B ^a   Zmijan, Robert ^b   Drobniewski, Francis ^c   Zhang, Xunli ^b   Jayasinghe, Suwan ^d   Elkington, Paul ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; HUMAN; LIMIT OF QUANTITATION; LUNG TUBERCULOSIS; MICROFLUIDICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CELL CULTURE TECHNIQUE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION; PROCEDURES; THEORETICAL MODEL;

BACTERIOLOGICAL TECHNIQUES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROFLUIDICS; MICROSPHERES; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS;

EID: 85014822141     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02073-16     Document Type: Article

References (44)

1. Cantón R, Morosini MI. 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 35:977–991. https://doi.org/10.1111/j.1574-6976.2011.00295.x.
2. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417–433. https://doi.org/10.1128/MMBR.00016-10.
3. WHO. 2014. Antimicrobial resistance: global report on surveillance 2014. World Health Organization, Geneva, Switzerland. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 6 January 2016.
4. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat Rev Microbiol 9:894–896. https://doi.org/10.1038/nrmicro2693.
5. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299–302. https://doi.org/10.1056/NEJMp1215093.
6. Bhavsar AP, Guttman JA, Finlay BB. 2007. Manipulation of host-cell pathways by bacterial pathogens. Nature 449:827–834. https://doi.org/10.1038/nature06247.
7. Scortti M, Lacharme-Lora L, Wagner M, Chico-Calero I, Losito P, Vázquez-Boland JA. 2006. Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Nat Med 12:515–517. https://doi.org/10.1038/nm1396.
8. Westermann AJ, Gorski SA, Vogel J. 2012. Dual RNA-seq of pathogen and host. Nat Rev Microbiol 10:618–630. https://doi.org/10.1038/nrmicro2852.
9. Schwartz MA, Chen CS. 2013. Cell biology. Deconstructing dimensionality. Science 339:402–404. https://doi.org/10.1126/science.1233814.
10. Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15:786–801. https:// doi.org/10.1038/nrm3904.
11. Nielsen EI, Friberg LE. 2013. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053–1090. https://doi.org/10.1124/pr.111.005769.
12. Eldholm V, Balloux F. 2016. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol 24:637–648. https://doi.org/10.1016/j.tim.2016.03.007.
13. Tezera LB, Bielecka MK, Chancellor A, Reichmann MT, Al Shammari B, Brace P, Batty A, Tocheva A, Jogai S, Marshall BG, Tebruegge M, Jayasinghe SN, Mansour S, Elkington PT. 2017. Dissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional model. Elife 6:e21283. https://doi.org/10.7554/eLife.21283.
14. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. 2016. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 16:e34–e46. https://doi.org/10.1016/S1473-3099(16)00070-0.
15. Udwadia ZF. 2012. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 67:286–288. https://doi.org/10.1136/thoraxjnl-2012-201663.
16. Warner DF, Mizrahi V. 2014. Shortening treatment for tuberculosis— to basics. N Engl J Med 371:1642–1643. https://doi.org/10.1056/NEJMe1410977.
17. Dartois V, Barry CE, III. 2013. A medicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23:4741–4750. https://doi.org/10.1016/j.bmcl.2013.07.006.
18. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM. 2015. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191:943–953. https://doi.org/10.1164/rccm.201410 -1801OC.
19. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46:279–286. https://doi.org/10.1038/ng.2878.
20. Russell DG. 2011. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 240:252–268. https://doi.org/10.1111/j.1600-065X.2010.00984.x.
21. Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE III, Mann M, Dartois V, Rubin EJ. 2016. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med 22: 531–538. https://doi.org/10.1038/nm.4073.
22. Al Shammari B, Shiomi T, Tezera L, Bielecka MK, Workman V, Sathyamoorthy T, Mauri F, Jayasinghe SN, Robertson BD, D’Armiento J, Fried-land JS, Elkington PT. 2015. The extracellular matrix regulates granuloma necrosis in tuberculosis. J Infect Dis 212:463–473. https://doi.org/10.1093/infdis/jiv076.
23. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464–1473. https://doi.org/10.1093/infdis/jit352.
24. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. https://doi.org/10.1371/journal.pone.0010777.
25. Conte JE, Jr., Golden JA, Duncan S, McKenna E, Zurlinden E. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 43:1329–1333.
26. Barrila J, Radtke AL, Crabbé A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson CA. 2010. Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol 8:791–801. https://doi.org/10.1038/nrmicro2423.
27. Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, Chen C, Dartois V, VanderVen BC, Russell DG. 2016. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med 213:809–825. https://doi.org/10.1084/jem.20151248.
28. Neuži P, Giselbrecht S, Länge K, Huang TJ, Manz A. 2012. Revisiting lab-on-a-chip technology for drug discovery. Nat Rev Drug Discov 11: 620–632. https://doi.org/10.1038/nrd3799.
29. Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH, Alves SE, Salmon M, Ferrante TC, Weaver JC, Bahinski A, Hamilton GA, Ingber DE. 2016. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 13:151–157. https://doi.org/10.1038/nmeth.3697.
30. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4:e1000204. https://doi.org/10.1371/journal.ppat.1000204.
31. Guirado E, Mbawuike U, Keiser TL, Arcos J, Azad AK, Wang SH, Schlesinger LS. 2015. Characterization of host and microbial determi nants in individuals with latent tuberculosis infection using a human granuloma model. mBio 6:e02537-14. https://doi.org/10.1128/mBio .02537-14.
32. Braian C, Svensson M, Brighenti S, Lerm M, Parasa VR. 2015. A 3D human lung tissue model for functional studies on Mycobacterium tuberculosis infection. J Vis Exp https://doi.org/10.3791/53084.
33. Kapoor N, Pawar S, Sirakova TD, Deb C, Warren WL, Kolattukudy PE. 2013. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS One 8:e53657. https://doi.org/10.1371/journal.pone.0053657.
34. Silva A, Lee BY, Clemens DL, Kee T, Ding X, Ho CM, Horwitz MA. 2016. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc Natl Acad Sci U S A 113:E2172–E2179. https://doi.org/10.1073/pnas.1600812113.
35. Horsburgh CR, Jr., Barry CE III, Lange C. 2015. Treatment of tuberculosis. N Engl J Med 373:2149–2160. https://doi.org/10.1056/NEJMra1413919.
36. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE, Pan ACEA Consortium. 2015. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 191:1058–1065. https://doi.org/10.1164/rccm.201407-1264OC.
37. Sackmann EK, Fulton AL, Beebe DJ. 2014. The present and future role of microfluidics in biomedical research. Nature 507:181–189. https://doi.org/10.1038/nature13118.
38. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197–3204. https://doi.org/10.1128/AAC.01681-08.
39. Dartois V. 2014. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12:159–167. https://doi.org/10.1038/nrmicro3200.
40. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T. 2010. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 5:e9823. https://doi.org/10.1371/journal.pone.0009823.
41. Workman VL, Tezera LB, Elkington PT, Jayasinghe SN. 2014. Controlled generation of microspheres incorporating extracellular matrix fibrils for three-dimensional cell culture. Adv Funct Mater 24:2648–2657. https://doi.org/10.1002/adfm.201303891.
42. Bange FC, Brown AM, Jacobs WR, Jr. 1996. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect Immun 64:1794–1799.
43. + T cells in human tuberculosis. Proc Natl Acad Sci U S A 97:12210–12215. https://doi.org/10.1073/pnas.210391497.
44. + T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol 175:7474–7483. https://doi.org/10.4049/jimmunol.175.11.7474.